Introduction
Lung cancer remains a devastating disease causing 6% of all deaths and accounting for over one quarter of all registrations of malignant neoplasms in males and 11% in females in industrialised countries [1] . European Cancer Registry data five-year survival rates remain disappointingly low, ranging from 6%-14%, with little improvement in the last two decades despite all therapeutic endeavours [2] . The reason for such poor results may include late presentation of the disease, problems of co-morbidity in a population of patients with a history of smoking, failure of current therapeutic modalities to impact on the natural history of the disease or the therapeutic nilhilism of treating physicians -such that patients are never referred to appropriate agencies. For the treating oncologist lung cancer is a huge challenge and there is much that can be done to benefit these patients despite only a small percentage being suitable for curative surgery or radiotherapy. In the last decade real advances have been made in the understanding of the relative roles of radio-and chemotherapy and how the benefits of each modality can be combined with surgery to improve therapeutic outcomes. The following case-study illustrates some of the practical issues in the management of non-small-cell-lung cancer and in the subsequent discussion some of the more controversial areas will be briefly explored.
Case study
A 63-year-old, retired lorry driver presented to the respiratory physicians at the Western General Hospital, Edinburgh, with a three-month history of non productive cough and slowly increasing shortness of breath that had failed to settle with several courses of antibiotics. His family doctor had arranged a chest X-ray which showed a mass below the right hilum measuring 4 cm in maximum diameter but no other abnormality in either lung field or mediastinum (Figure 1 ).
At bronchoscopy, he was noted to have friable tumour at the orifice of the right lower lobe, extending into the right bronchus intermedius. Biopsy of this showed moderately differentiated squamous cell carcinoma. He was otherwise fit, with an exercise tolerance of about one mile on the flat and no past history of note. Over the last four months he had unintentionally lost approximately 3 kg in weight (4% of body weight).
CT scan of the chest confirmed a 4.6 cm proximal tumour at the apex of the right lower lobe and in addition, a 2 cm subcarinal node (Figures 2 and 3) . Several other small nodes were noted in the mediastinum but none measured more than lcm in diameter. The remainder of the lung parenchyma was clear and the liver and adrenal glands appeared normal. His FEV1 was 1.7 with anFVCof2.6.
He was reviewed by the cardiothoracic surgeons who confirmed the findings on rigid bronchoscopy and proceeded with mediastinoscopy. At mediastinoscopy, biopsies were taken from the subcarinal, paratracheal and pretracheal areas. The biopsies from the subcarinal and pretracheal nodes revealed metastatic carcinoma and he was therefore staged as having T2N2 non-smallcell lung cancer.
On the basis of the mediastinal lymphadenopathy he was deemed inoperable and was referred for an oncological opinion. Following discussion of treatment options, it was decided to give him neo-adjuvant chemotherapy with mitomycin-C (6 mg/m 2 ), ifosfamide (3 g/m 2 ) and cisplatin (50 mg/m 2 , MIC chemotherapy) given on day 1 of a 21 day cycle.
He received three cycles, which he tolerated well apart from alopecia and generalised lethargy, although his third cycle was delayed one week because of neutropenia. His repeat CT scan showed a partial response in the primary tumour which now measured 2.5 cm in diameter with the subcarinal node being 1 cm in max- imum diameter. He went on to recieve radical radiotherapy.
Three-dimensional CT planning with a beams' eye view facility was used to localise the gross tumour volume and areas at risk which included the right hilum and lymph nodes within the subcarinal, precarinal, pretracheal and paratracheal areas. A 1 cm margin around the gross tumour volume denned the clinical target volume (CTV) with a further 0.5 cm in the lateral plain and lcm in the craniocaudal direction to account for variations in day to day set up and chest movement during treatment (the planning target volume). Conformal blocks were used to exclude normal tissue from the treatment volume. A three field technique was used and the patient recieved 5250 cGy in 20 fractions over 27 days.
A chest X-ray, one month following completion of treatment, showed little change in the size of the right lung tumour, but a CTscan, three months after completion of radiotherapy, showed no evidence of residual tumour, although there was some scarring at the right hilum consistent with radiation fibrosis.
The patient remained well and symptom free for 12 months, until he returned to the clinic complaining of increasing dyspnoea and a 10-day history of neck swelling.
On examination, he was noted to have signs of superior vena caval obstruction. A chest X-ray showed a large, right paratracheal shadow consistent with upper mediastinal lymphadenopathy, lying within the previous radiotherapy field, and regrowth of the right hilar mass.
Venography confirmed extrinsic compression of the superior vena cava. Under fluoroscopic control, an expandable metal stent was inserted in to the SVC across the narrowed region. This resulted in a rapid relief of his symptoms and signs, although he continued to complain of dyspnoea on exertion. He was offered further palliative chemotherapy which he was keen to accept.
He was retreated with two further cycles of MIC deriving some symptomatic benefit. Unfortunately, after the third cycle he developed severe low back pain and a bone scan showed increased uptake in L3, L4 and in several ribs consistent with metastatic disease. He received a single fraction of palliative radiotherapy to his lumbar spine and declined any further chemotherapy.
Supportive care at home was arranged from the local hospice and he died six weeks later with liver metastases and bronchopneumonia.
Discussion

Histology and staging
Thirty-five percent to 40% of lung cancers are of squamous histology, another 25%-35% are adenocarcinomas and 20%-30% are of small-cell histology. Large cell carcinoma accounts for about 10% but the incidence is decreasing as improved pathological techniques allow many cases previously identified as large-cell carcinoma to be correctly classified as adenocarcinomas. As a result, adenocarcinoma has now overtaken squamous-cell carcinoma as the most common histology seen in North America. Frequently, lung cancer may exhibit two or more histologic subtypes within the same specimen, reflected in their response to the various modalities to treatment.
Staging of NSCLC is according to the UICC TNM system [3] . The primary tumour is divided into four categories depending on size, site, involvement of local structures and proximity to the carina. This is of surgical relevance because tumours less than 2 cm from the carina or invading mediastinal structures are technically inoperable. Lymph node staging is subdivided into bronchopulmonary (N)), ipsilateral medistinal (N 2 ) and contralateral or supraclavicular disease (N 3 ), and metastatic spread as absent or present (M o or M|). Furthermore four stages of lung cancer have been identified within the TNM system which can accurately define significant differences in five-year survival depending on the stage of disease at diagnosis [4] . Other independent pre-treatment prognostic factors include performance status, histology and significant weight loss, usually described as more than 10% of body weight.
Investigations
Accurate staging of the disease is essential if appropriate therapy is to be initiated. The chest X-ray will be abnormal in 95% of cases. A CT scan can suggest local invasion of adjacent stuctures such as the mediastinum or vertebrae. In addition it may show mediastinal lymph node enlargement and other secondary pulmonary nodules or a pleural effusion. The scan should extend to the level of the upper abdomen to include the liver and adrenal glands. Three early morning sputum samples can provide confirmation of a diagnosis in 80% of central tumours. However more usually a bronchoscopy can provide a histological diagnosis in 90% of cases where a tumour is visible. It may also indicate whether a tumour is operable in terms of its proximity to the carina. If a patient is considered operable after the above investigations mediastinoscopy should be performed prior to proceeding to surgery. Even if enlarged lymph nodes are seen on the CT scan mediastinoscopy must be performed because in 30% of those with enlarged nodes biopsies will not reveal any evidence of spread.
Local disease
The prime treatment modality for localised disease is surgery, but unfortunately less than 20% of cases are suitable for surgical resection at diagnosis, i.e., stages T, or T 2 , N o or Ni. Early chest wall invasion (T 3 ) may be resectable and if there is no nodal disease (N o ), may be associated with an 80% five-year survival rate. Most surgeons would consider the presence of N 2 disease (ipsilateral mediastinal lymph node involvement) as an indication of inoperability. If N 2 disease is diagnosed pre-operatively either by non-invasive or invasive staging techniques, less than 10% of all patients treated surgically survive five years. The optimal management of these patients remains unclear. If the primary tumour and involved nodes can be encompassed in the same field of irradiation, radiotherapy is an option. However, even if the local disease can be controlled, these patients tend to relapse with distant metastases.
Radical radiotherapy
High-dose radiotherapy should be considered in those patients who are medically unfit for surgical resection or who refuse an operation. In such cases radiotherapy can result in five-year survival rates in excess of 30% [5] .
More controversial is the role of high-dose radiotherapy in locally advanced, non-metastatic NSCLC. Data from series of patients treated in the 1970s and 80's suggested that five-year survival rates were disappointingly low, at around 5%-7% [6] [7] [8] . However these dismal figures probably reflect the inappropriate selection of patients for treatment and technical inadequacies of the radiotherapy in previous decades. Advanced age is not a contraindication but suitable patients should be of WHO performance status 0, 1 or 2, with less than 10% weight loss. Generally, tumours greater than 6 cm in maximum diameter are unsuitable because the chances of obtaining local control with conventional doses is remote and the larger the tumour, the greater the volume of normal lung irradiated with attendant risk of significant morbidity from radiation pneumonitis. This is particularly so in tumours of the lower lobes.Thus the patients' pre-morbid lung function must be adequate given that it may deteriorate following irradiation.
Modern radiotherapy technique should include megavoltage irradiation, CT simulation, and tissue inhomogeneity correction at the very least. Unfortunately, with standard radiotherapy techniques delivering a dose of 60-65 Gy in 2 Gy fractions or equivalent, less than 20% of patients will obtain a complete response at three months [9] . Recent technical innovations have allowed ways of safe dose escalation in an effort to improve local control rates. Three dimensional CT planning and conformal blocking has provided a means of ensuring a homogenous dose to the target volume whilst decreasing irradiation of surrounding normal tissues. The lung and spinal cord are the dose-limiting structures when irradiating lung tumours and if the dose to these normal tissues can be minimised with the above techniques then dose-escalation to the primary tumour may result in greater local control [10] .
There have been many randomised trials exploring the use of hyperfractionation and accelerated radiation in NSCLC with varying results. These two radiobiological manipulations have been combined in the CHART regimen (Continuous Hyperfractionated Accelerated Radiotherapy). Three fractions are given each day with at least a six-hour gap and the whole course is completed in 12 days. This technique has shown a significant improvement in two-year survival (Figure 4 ) compared to standard radiotherapy (29% vs. 20%) with acceptable acute and long-term toxicity [11] .
Chemotherapy for non-metastatic disease
Unfortunately distant relapse is an all too common event in NSCLC even if the primary tumour can be controlled. The use of systemic chemotherapy offers the theoretical advantage of destroying micrometastatic disease whilst improving local control rates and can be administered in the neo-adjuvant or adjuvant setting with surgery or radiotherapy. If given concurrently with irradiation, it may also act as a radiosensitiser but increased toxicity often necessitates dose-reductions [12] . Most individual randomised trials comparing cisplatincontaining chemotherapy and radical radiotherapy to radiotherapy alone have failed to show any survival benefit but have shown significant reductions in distant relapse rate [9, [12] [13] [14] . This lack of survival benefit may result from the small number of patients accrued to these trials or from inappropriate selection of patients. However poor local control rates, even with combined modality treatment, remain the predominant problem. It has taken a large meta-analysis to show a survival benefit for the use of cisplatinum-containing chemotherapy. The 18% reduction in the risk of death is equivalent to an absolute benefit of 4% at two years and 2% at five years [15] .
Although this benefit is small, given the number of patients with lung cancer each year, these results suggest that if chemotherapy is given to appropriate cases, a large number of deaths could be prevented. A further advantage of neo-adjuvant chemotherapy is that the resulting tumour shrinkage may allow smaller volumes of irradiation to be used, so reducing normal tissue damage. Surprisingly, the meta-analysis failed to show that any group specified by age, sex, performance status, histological type or stage benefitted any more or less from chemotherapy. However, it must be remembered that patients randomised within these trials are highly selected and do not represent the general population of patients with NSCLC. It may be that molecular characterisation can provide a more accurate indication of chemosensitivity in the future to aid in appropriate patient selection.
Several small randomised trials have also shown a survival benefit for induction cisplatin-containing chemotherapy prior to surgery compared to surgery alone, for stage IIIA NSCLC. The addition of pre-operative irradiation in a trimodality approach may further improve survival but this hypothesis needs testing in a phase III setting before it could be considered standard.
Palliative treatment ofnsclc
Unfortunately the palliation of symptoms is the main treatment aim for the majority of patients at presentation and constitutes most of the workload of any department treating lung cancer. A holistic, multidisciplinary approach is essential, involving physicians, specialist hospital and home nursing care, occupational and physiotherapists and hospice support. Specific symptoms, such as breathlessness, pain, anorexia and anxiety should be sought and managed appropriately.
For the clinical oncologist, the treatment options availabe for palliation have increased considerably over the last decade or so:
External beam radiotherapy (EBRT) remains an excellent form of palliation and in poor performance status patients a single fraction of 1000 cGy is as effective as two or more (1700 cGy/two fractions over one week or 3000 cGy/10 fractions over two weeks) [16, 17] in relieving symptoms with no increase in toxicity (Table 1 ). For good performance status patients in whom curative treatment is inappropriate, a higher, fractionated dose (3900 cGy/13 fractions) has been shown to improve median survival by two months although rates of palliation are no different to shorter fractionation regimens [18] . Most patients with locally advanced or metastatic disease are symptomatic at presentation and require some form of palliation immediately. For the minority that are asymptomatic, the role of immediate palliative radiotherapy versus radiotherapy delayed until time of symptomatic progression is being investigated in a MRC randomised trial.
Other local palliative treatments include: Endobronchial brachytherapy. With the advent of high-dose rate afterloading equipment a dose of 15-20 cGy can be delivered to the bronchial wall in a few minutes. As a first line palliative treatment it appears to have similar symptomatic response rates to EBRT [19] .
Tracheobronchial stenting. A covered expandable metal stent can be placed in the narrowed lumen of the trachea and bronchi. Prior treatment with the Nd-YAG laser is usually necessary except in cases of pure extrinsic compression. It may be especially useful in the management of tracheo-bronchial fistulas. Relief of dyspnoea and cough is rapid and complications, namely stent migration, retention of secretions and incomplete tumour coverage are rare [20] .
Superior vena cava obstruction
Superior vena caval obstruction (SVCO) occurs in 5%-10% of patients with lung cancer. Whilst it is a medical emergency in only a small percentage of these cases, the symptoms can be distressing. Glucocorticoid therapy may temporarily be helpful, but radiotherapy (or chemotherapy for chemosensitive tumours) has been the traditional mainstay of treatment. In this case-study, radiotherapy was contraindicated due to the patients' previous treatment. The advent of intravascular metal stents has provided a real therapeutic advance in the management of SVCO [21] . The stent is introduced percutaneously via an arm or a femoral approach. Thrombus within the SVC is not a contraindication as the catheter can be used to deliver thrombolytics directly, but anticoagulation following the procedure may be advisable. Stenting relieves obstruction in 90% of patients and complication rates are low -with misplacement 10%, stent migration 5%, occlusion 10%, and cardiac arrythmias being the most commonly reported.
Chemotherapy in the palliative setting
For patients unsuitable for radical treatment, chemotherapy may provide useful palliation in selected patients.
The combination of mitomycin-C, ifosfamide and cisplatinum can lead to responses in 52% of patients with localised inoperable disease and 31% in extensive disease and result in improved quality of life compared to best supportive care [22] [23] [24] . Symptomatic improvement is seen in 69% of patients treated with mitomycin-C, vinblastine and cisplatinum (MVP) [25] . Furthermore, the recent meta-analysis of 11 trials has shown a significant survival benefit to cisplatin-containing chemotherapy compared to best supportive care, with an improvement in survival of 10% at one year and a prolongation of median survival of 1.5 months [15] . This modest increase has led some to question the use of chemotherapy in advanced disease. The meta-analysis also shows the detrimental effect on survival of longterm alkylating agents, commomly used in the 1970s, in both the advanced and early disease settings.
The last two decades has seen the testing and incorporation of novel chemotherapy drugs into clinical use. Vinorelbine is a vinca alkaloid whose concentrations in human lung are 300-fold greater than plasma levels after intravenous dosing. The combination of cisplatinum and vinorelbine has been shown to improve survival compared to vinorelbine alone or cisplatin and vindesine [26] . Similarly, cisplatin plus paclitaxel may be superior to cisplatin plus etoposide [27] . For less fit patients the toxicities of these regimens may preclude their use. In this setting gemcitabine, a nucleoside analogue, may have a role to play, giving response rates of about 20% to single-agent use, with minimal toxicity.
